Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,359 stopped studies mapped to Non-Hodgkin Lymphoma and descendants · 89% state a reason
Over the 1,359 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04676087 | Mogamulizumab and Extracorporeal Photopheresis for the Treatment of Sezary Syndrome or… | Phase 1 / Phase 2 | terminated | Dec 19, 2020 | Emory University | Lack of funding | Funding |
| NCT01843868 | Emesis Control Study in Non-Hodgkin Lymphoma Patients Receiving R-CHOP | N/A | withdrawn | May 1, 2013 | Australasian Leukaemia and Lymphoma Group | Study halted prematurely, prior to enrollment of first participant due to protracted logistical and… | Enrollment / accrual |
| NCT00848601 | Safety of SGI-1776, A PIM Kinase Inhibitor in Refractory Prostate Cancer and… | Phase 1 | terminated | Feb 20, 2009 | Astex Pharmaceuticals, Inc. | The dose limiting toxicity of cardiac QTc prolongation was identifiedin the phase 1 study in… | Safety / toxicity |
| NCT04852822 | Immune Response to SARS-CoV-2 (COVID-19) Vaccines in Patients With Chronic Lymphocytic… | — | terminated | Apr 21, 2021 | University of Washington | The study ended earlier than anticipated due to slow accrual. | Enrollment / accrual |
| NCT04545333 | The clonoSEQ® Watch Registry | — | terminated | Sep 11, 2020 | Adaptive Biotechnologies | Sufficient data collected. | Other (stated, no rule matched) |
| NCT05908396 | Evaluation of IGM-2644 in Adults With Relapsed and/or Refractory Multiple Myeloma | Phase 1 | terminated | Jun 18, 2023 | IGM Biosciences, Inc. | Company Decision | Sponsor / business decision |
| NCT01296555 | A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in… | Phase 1 | terminated | Feb 15, 2011 | Genentech, Inc. | The Sponsor discontinued the manufacturing and development of taselisib due to modest clinical… | Drug supply |
| NCT04806035 | Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell… | Phase 1 | terminated | Mar 19, 2021 | TG Therapeutics, Inc. | Strategic/Business Decision | Sponsor / business decision |
| NCT04082936 | A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory… | Phase 1 / Phase 2 | terminated | Sep 10, 2019 | IGM Biosciences, Inc. | Strategic Pipeline Prioritization: Clinical development of imvotamab in autoimmune diseases… | Sponsor / business decision |
| NCT05360238 | Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or… | Phase 1 / Phase 2 | terminated | May 4, 2022 | Mustang Bio | Business reasons | Sponsor / business decision |
| NCT05645744 | Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell… | — | terminated | Dec 9, 2022 | Mustang Bio | Business Reasons | Sponsor / business decision |
| NCT03671590 | Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With… | Phase 1 | terminated | Sep 14, 2018 | TG Therapeutics, Inc. | Strategic/Business Decision | Sponsor / business decision |
| NCT05272813 | A Study to Investigate the Efficacy and Safety of MS-553 in CLL/SLL | Phase 1 / Phase 2 | terminated | Mar 9, 2022 | Shenzhen MingSight Relin Pharmaceuticals Co., Ltd. | The study is terminated due to major protocol revisions. | Other (stated, no rule matched) |
| NCT05720052 | A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma | Phase 1 / Phase 2 | terminated | Feb 9, 2023 | MingSight Pharmaceuticals, Inc | The study is terminated due to major protocol revisions. | Other (stated, no rule matched) |
| NCT05050305 | Marizomib Central Nervous System (CNS) | Phase 2 | withdrawn | Sep 20, 2021 | Dana-Farber Cancer Institute | Study support withdrawn | Other (stated, no rule matched) |
| NCT04072393 | Cardiac Rehabilitation for Patients Receiving Radiation Therapy for Thoracic Cancers | N/A | terminated | Aug 28, 2019 | Washington University School of Medicine | Futility | Efficacy / futility |
| NCT05936229 | Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy | Phase 1 / Phase 2 | withdrawn | Jul 7, 2023 | Fred Hutchinson Cancer Center | Study closed before opening to accrual, no participants enrolled | Enrollment / accrual |
| NCT02110563 | Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors,… | Phase 1 | terminated | Apr 10, 2014 | Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | Sponsor Decision | Sponsor / business decision |
| NCT03088709 | Haploidentical Stem Cell Transplantation Using Post-Transplant Cyclophosphamide | Phase 2 | terminated | Mar 23, 2017 | Loyola University | Poor accrual | Enrollment / accrual |
| NCT05820763 | Selinexor and Lenalidomide for Consolidation and Maintenance Treatment in Multiple… | Phase 2 | withdrawn | Apr 20, 2023 | Washington University School of Medicine | Study sponsor decided to close study. | Sponsor / business decision |
| NCT02400242 | Study of ACY-241 Alone and in Combination With Pomalidomide and Dexamethasone in Multiple… | Phase 1 | terminated | Mar 27, 2015 | Celgene | Lack of efficacy | Efficacy / futility |
| NCT04933617 | Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and… | Phase 1 | terminated | Jun 22, 2021 | National Cancer Institute (NCI) | The study was terminated early because copanlisib was removed from the market by the Food and Drug… | Drug supply |
| NCT02295722 | GEMHDM2014 : Gem-HDM HDT and ASCT for Relapsed/ Refractory Lymphoma(GEMHDM2014) | Phase 1 / Phase 2 | terminated | Nov 20, 2014 | AHS Cancer Control Alberta | It did not show a significant benefit to justify completing the full target accrual. | Enrollment / accrual |
| NCT05105412 | Lenalidomide and Gemcitabine in Relapsed or Refractory Peripheral T-cell Lymphomas | Phase 1 / Phase 2 | terminated | Nov 3, 2021 | National Health Research Institutes, Taiwan | The resolution of DSMB | Other (stated, no rule matched) |
| NCT02863991 | Oral ONC201 in Relapsed/Refractory Multiple Myeloma | Phase 1 / Phase 2 | terminated | Aug 11, 2016 | Jazz Pharmaceuticals | This study was terminated due to a change in corporate priorities. The decision to terminate the… | Safety / toxicity |
| NCT03777410 | Mass Accumulation Rate (MAR) as a Predictive Biomarker in Multiple Myeloma | — | terminated | Dec 17, 2018 | Travera Inc | Insufficient pace of enrollment due to changes in MM SOC practices | Enrollment / accrual |
| NCT04111107 | Precision Medicine for Patients With Identified Actionable Mutations | Phase 2 | terminated | Oct 1, 2019 | Wake Forest University Health Sciences | PI left the institution and site decided not to continue the study | Investigator |
| NCT05204160 | Pembrolizumab as Salvage Therapy for the Treatment of Multiple Myeloma in Patients… | Phase 2 | withdrawn | Jan 24, 2022 | Emory University | slow accrual | Enrollment / accrual |
| NCT03448978 | Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma | Phase 1 | terminated | Feb 28, 2018 | Cartesian Therapeutics | Phase 1 enrollment completed. Further clinical development terminated | Enrollment / accrual |
| NCT04352205 | Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With… | Phase 2 | terminated | Apr 20, 2020 | Emory University | Slow accrual | Enrollment / accrual |
| NCT05000450 | Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients… | Phase 1 / Phase 2 | terminated | Aug 11, 2021 | Allogene Therapeutics | Terminated (Halted Prematurely) | Other (stated, no rule matched) |
| NCT01670994 | QUILT-3.020: A Study of ALT-801 in Patients With Relapsed or Refractory Multiple Myeloma | Phase 1 / Phase 2 | terminated | Aug 23, 2012 | Altor BioScience | Patient population did not benefit from single agent treatment. | Other (stated, no rule matched) |
| NCT04074330 | A Study of TAK-981 Given With Rituximab in Adults With Relapsed or Refractory… | Phase 1 / Phase 2 | terminated | Aug 30, 2019 | Takeda | Enrolment Challenges | Enrollment / accrual |
| NCT04956302 | Panobinostat in Combination With Daratumumab, Bortezomib and Dexamethasone for the… | Phase 1 | terminated | Jul 9, 2021 | Abdullah Khan | PI Decision | Other (stated, no rule matched) |
| NCT06232707 | A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care…(ALUMMINATE) | Phase 3 | withdrawn | Jan 31, 2024 | Celgene | Business objectives have changed | Sponsor / business decision |
| NCT05048732 | Imaging Apoptosis for Lymphoma Treatment Response | Early Phase 1 | terminated | Sep 17, 2021 | Washington University School of Medicine | Futility | Efficacy / futility |
| NCT03789864 | Biodynamic Imaging Utility in Predicting Response to Gemcitabine Chemotherapy in Mycosis…(BDI) | N/A | terminated | Dec 31, 2018 | Indiana University | Lack of accrual in a timely fashion | Enrollment / accrual |
| NCT06210750 | Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute… | Phase 2 | withdrawn | Jan 18, 2024 | National Cancer Institute (NCI) | Other - Protocol moved to Disapproved | Other (stated, no rule matched) |
| NCT04722601 | A Dose-Finding and Efficacy Study of Venetoclax, CC-486, and Obinutuzumab in Follicular… | Phase 1 / Phase 2 | terminated | Jan 25, 2021 | University of Chicago | funding | Funding |
| NCT04718610 | Heart Rate Variability, Vagus Nerve and Cancer | N/A | terminated | Jan 22, 2021 | Centre Hospitalier Henri Duffaut - Avignon | Heart rate measurement error | Other (stated, no rule matched) |
| NCT05022797 | Reduction of MTX Levels After Glucarpidase Treatment in DLBCL Patients at Risk of CNS | Phase 2 | terminated | Aug 26, 2021 | Fundacion CRIS de Investigación para Vencer el Cáncer | closed because of low recruitment | Enrollment / accrual |
| NCT04242121 | The Risk Stratification in Patients With Multiple Myeloma Based on Fluorescence Flow… | — | terminated | Jan 27, 2020 | Ivan S Moiseev | poor recruitment | Enrollment / accrual |
| NCT02624388 | Study of Genistein in Pediatric Oncology Patients (UVA-Gen001)(UVA-Gen001) | Phase 2 | terminated | Dec 8, 2015 | University of Virginia | Poor enrollment | Enrollment / accrual |
| NCT06400264 | Testing Nivolumab and BMS-986016 (Relatlimab) as Potentially Targeting Treatment in… | Phase 2 | withdrawn | May 6, 2024 | National Cancer Institute (NCI) | No result will be reported- no patient accrued. Status Withdrawn: Study halted prematurely, prior… | Enrollment / accrual |
| NCT03225716 | A Study of Ulocuplumab And Ibrutinib in Symptomatic Patients With Mutated CXCR4… | Phase 1 | terminated | Jul 21, 2017 | Dana-Farber Cancer Institute | Sponsor decision to end follow-up early | Sponsor / business decision |
| NCT05950113 | CART-BCMA/CS1 in Treating Patients With Relapsed or Refractory Multiple Myeloma | Phase 1 | withdrawn | Jul 18, 2023 | Jonsson Comprehensive Cancer Center | The study was withdrawn before opening | Other (stated, no rule matched) |
| NCT04407442 | Daratumumab, Azacitidine, and Dexamethasone for Treatment of Patients With Recurrent or… | Phase 2 | terminated | May 29, 2020 | University of California, San Francisco | Slow enrollment and change in sponsor direction | Enrollment / accrual |
| NCT04685525 | Mycobiome Supporting Diet to Reduce GI Toxicity Associated With ASCT | N/A | withdrawn | Dec 28, 2020 | Case Comprehensive Cancer Center | Administrative decision | Other (stated, no rule matched) |
| NCT00775502 | Phase 1/2 Study of Anti GM-2 Monoclonal Antibody To Treat Multiple Myeloma | Phase 1 | terminated | Oct 20, 2008 | Kyowa Kirin Co., Ltd. | lack of efficacy in Multiple myeloma | Efficacy / futility |
| NCT04995536 | CpG-STAT3 siRNA CAS3/SS3 and Localized Radiation Therapy for the Treatment of… | Phase 1 | withdrawn | Aug 9, 2021 | City of Hope Medical Center | no accrual | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Aug 13, 2024source: clinicaltrials